Categories: NewsPatient Care

DeepSight™ Technology Receives First FDA 510(k) Clearance for NeedleVue™ LC1 Ultrasound System

Bringing Clarity and Confidence to Ultrasound-Guided Interventional Procedures

SANTA CLARA, Calif., Aug. 13, 2025 /PRNewswire/ — DeepSight Technology, a medical imaging pioneer, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its NeedleVue LC1 Ultrasound System.

This clearance marks an important step forward in DeepSight’s development of its NeedleVue and OnPoint technologies that will work in tandem with the NeedleVue LC1 Ultrasound System to transform image-guided procedures. “This is a foundational milestone in our mission to deliver crystal clear, sub millimeter level guidance inside the body,” said Nader Sadrzadeh CEO of DeepSight. “We have developed the next generation sensor technology for enhancing ultrasound where it what matters most—clear visualization, procedural efficiency, and user confidence. We’re just getting started and look forward to building on this achievement as we expand our clinical and commercial momentum in the months ahead.”

To learn more about the NeedleVue LC1 Ultrasound System and DeepSight’s mission to advance procedural ultrasound, visit www.deepsight.com.

Visit DeepSight at the upcoming LSI’25 Europe meeting in London September 7th – 11th and Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference in Barcelona, September 13–17, to experience NeedleVue technology firsthand.

About DeepSight Technology
DeepSight Technology, founded in 2019 by Nader Sadrzadeh, Lan Yang, and Anand Chandrasekher, is built on a bold vision — to revolutionize medical imaging through proprietary sensing technology. With offices in the San Francisco Bay Area and Clayton, Missouri, DeepSight aims to extend the capabilities of ultrasound across diagnostic, therapeutic, surgical, and interventional applications —advancing patient care and improving public health worldwide. Our next-generation sensor technology will transform ultrasound, with the goal to deliver exceptional clarity, pinpoint precision, and unparalleled confidence for clinicians in every procedure.

View original content to download multimedia:https://www.prnewswire.com/news-releases/deepsight-technology-receives-first-fda-510k-clearance-for-needlevue-lc1-ultrasound-system-302529247.html

SOURCE DeepSight Technology, Inc.

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

18 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

18 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

2 days ago